



Antibiotics vs. Phage Therapy

Guest Editor:

Prof. Dr. Grzegorz Węgrzyn

Department of Molecular Biology,
University of Gdańsk, Gdańsk,
Poland

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editor

Dear Colleagues,

Antibiotic-resistance crisis caused requirement for developing novel therapeutic approaches. Phage therapy (the use of bacteriophages to combat bacteria) is one of them. However, antibiotics are still important weapon in our fight against pathogenic microorganisms, and must be considered if we assess any novel approaches. This special issue is focused on comparison and interplay between antibiotics and phage therapy. Topics of interest include, but are not limited to, following issues: (1) comparing efficacy and safety of the use of antibiotics and phage therapy, (2) identification and characterization of newly discovered antimicrobial chemical agents and bacteriophages, and (3) assessing effectiveness of combined therapies using antibiotics together with bacteriophages to combat bacterial infections. Both original papers and review articles are welcome, and will be considered for publication in this special issue of “Antibiotics”.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)